Elevance Health (ELV) Slips Ahead of Q1 Earnings; Jefferies Trims Target

Recent Developments

Elevance Health Inc. (NYSE: ELV) is approaching its first-quarter 2025 earnings report, due Wednesday morning, with investors focused on results from the health insurance provider. Ahead of the release, Jefferies analyst David Windley maintained a Buy rating on ELV but lowered the price target from $395 to $391, according to Benzinga. The modest target reduction signals some caution even as Windley holds a constructive view on the stock.

The earnings report will be closely watched for signs of how Elevance Health is managing medical cost pressures that have weighed on the managed care sector broadly. No specific guidance figures or pre-release metrics have been disclosed by the company ahead of Wednesday's announcement.

Financial Snapshot

Elevance Health shares are trading at $319.36, down $3.69, or 1.14%, on the day. The previous close was $323.05. Over the past 52 weeks, the stock has traded in a range of $273.71 to $437.99, placing the current price near the lower half of that range.

The stock's position well below its 52-week high of $437.99 reflects the broader pressure on managed care names over the past year, driven by elevated medical utilization trends across the industry.

Wall Street View

Analyst sentiment on Elevance Health remains broadly positive, though the majority of coverage sits in Hold territory. According to consensus data as of April 1, 2026, the breakdown is as follows: 5 Strong Buy, 10 Buy, 13 Hold, 0 Sell, and 0 Strong Sell. This distribution is unchanged from the prior period ending March 1, 2026, suggesting no material shift in analyst positioning over the past month.

Jefferies' decision to trim its price target from $395 to $391 is the most recent change on record. At $391, that target represents roughly 22% upside from the current price of $319.36. No additional price target data from other firms is available at this time.

Key Takeaways

• Elevance Health shares fell $3.69 (1.14%) to $319.36, with Q1 2025 earnings due Wednesday morning.
• Jefferies analyst David Windley maintained a Buy rating but cut the price target from $395 to $391, per Benzinga.
• Wall Street consensus as of April 1, 2026 stands at 15 Buy-equivalent ratings and 13 Holds, with zero Sell recommendations.
• At $319.36, ELV trades near the lower half of its $273.71–$437.99 52-week range, leaving meaningful distance from analyst price targets.